IsoPet generates revenues from each treatment administered. The company has implemented strategies to enhance profitability, such as combining multiple treatments into a single production run to reduce per treatment production and shipping costs. Also, the company has introduced a clinic certification fee. The company treated 6 patients in the last 2 months and are scheduled for 6 patients in this month alone. More patients treated equals lower costs for the company. isoPet is gaining traction and may be close to profitability, if we're not there already. What is real exciting though is that we are expecting the 90 day human trial results this month or possibly early April(pending followup visits by patients in a timely fashion).I suspect the IDE submission will be shortly after the 90 day results are received.
Market Data 
Markets 
AI
